Project Oncology®

187 Folgen

1. Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

   Vom: 23.6.2025
2. Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care

   Vom: 10.6.2025
3. Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden

   Vom: 5.6.2025
4. Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery

   Vom: 5.6.2025
5. Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study

   Vom: 3.6.2025
6. First Results From Cohort 4 of the SunRISe-1 Trial

   Vom: 1.5.2025
7. Trial in Progress: Phase 3 MoonRISe-3 Study

   Vom: 1.5.2025
8. HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

   Vom: 15.4.2025
9. Targeting CD123 in AML: The Latest Therapeutic Advancements

   Vom: 11.4.2025
10. Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies

    Vom: 7.4.2025
11. Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

    Vom: 28.3.2025
12. AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

    Vom: 14.3.2025
13. Chemotherapy Strategies for Metastatic PDAC

    Vom: 13.1.2025
14. Diagnosis and Management of Metastatic PDAC

    Vom: 13.1.2025
15. Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

    Vom: 8.1.2025
16. Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

    Vom: 7.1.2025
17. Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data

    Vom: 7.1.2025
18. Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

    Vom: 2.1.2025
19. Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

    Vom: 31.12.2024
20. Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

    Vom: 23.12.2024